News CMS's Medicare price negotiations start round three The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.
News MSD said to have pulled back from Revolution Meds deal Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.
News Data builds behind Moderna's skin cancer vaccine Five-year results with Moderna/MSD's melanoma jab show a 49% reduction in disease progression or death, boding well for phase 3 data later this year.
News JPM: Illumina launches 'unprecedented' disease biology atlas Illumina says its new Billion Cell Atlas can be used to identify and validate drug targets and train AI models used in drug discovery.
News Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
News Nine more companies sign pricing deals with Trump Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
